68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the dosimetry, safety and the detection rate of 68Ga-THP-PSMA PET/CT for
identifying the site of prostate cancer metastasis and relapse. It is also to evaluate the
association of clinical/pathologic features and 68Ga-THP-PSMA PET/CT detection rate and
compare 68Ga-THP-PSMA PET/CT with other imaging procedure.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine